|
PVTA, LOCN, XDSL, KGJI, ROSV, ALXA
Our Stocks to Watch tomorrow include Preventia Inc. (OTCBB: PVTA), Locan Inc. (OTCBB: LOCN), mPhase Technologies Inc. (OTCBB: XDSL), Kingold Jewelry Inc. (NASDAQ: KGJI), Rostock Ventures Corp. (OTCBB: ROSV) and Alexza Pharmaceuticals Inc. (NASDAQ: ALXA).
PREVENTIA INCORPORATED (OTCBB: PVTA)
"Up 300.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/PVTA.php
Preventia, Inc., a cognitive learning and development company, builds software tools for enhancing occupational and brain health and performance. It is developing a series of computer-based exercises for adults and children to improve working memory capacity. The company was founded in 2010 and is based in Toronto, Canada.
PVTA News:
No recent news for Preventia, Inc. (OTCBB: PVTA).
LOCAN INCORPORATED (OTCBB: LOCN)
"Up 100.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/LOCN.php
Locan, Inc. does not have significant operations. The company intends to acquire or merge with one or more businesses ventures. Previously, it was engaged in the production and distribution of ready-to-eat sandwiches under the Cuban Foods label. Locan, Inc. was founded in 2008 and is based in Bartlesville, Oklahoma.
LOCN News:
No recent news for Locan, Inc. (OTCBB: LOCN).
MPHASE TECHNOLOGIES INCORPORATED (OTCBB: XDSL)
"Up 12.50% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/XDSL.php
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website at www.mpowertech.com.
XDSL News:
June 28 - mPhase Developing Launch Strategy for New Automotive and Marine Product Featuring Advanced Battery Technology
mPhase Technologies, Inc. (OTCBB: XDSL) said that it is developing its launch strategy for its new automotive and marine product with an experienced marketing agency and launch firm. The product featuring advanced battery technology has been developed in cooperation with a world-renowned automotive company known for its timeless and unmistakable design capabilities.
Although the company said it would unveil the new product in early spring it has decided to keep the product under wraps in order to protect the design from being reversed engineered in an attempt to have a first to market advantage.
The new product features a powerful product encased in small footprint with an extraordinary look for its product category.
KINGOLD JEWELRY INCORPORATED (NASDAQ: KGJI)
"Up 26.87% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/KGJI.php
Kingold Jewelry, Inc., centrally located in Wuhan City, China's fourth largest city, was founded in 2002 and today is one of China's leading designers and manufacturers of 24-karat gold jewelry, ornaments and investment-oriented products. The Company sells both directly to retailers as well as through major distributors across China. Kingold has received numerous industry awards and has been a member of the Shanghai Gold Exchange since 2003.
KGJI News:
May 29 - Kingold Jewelry Signs Agreement with Shenzhen-based Wholesaler to Process Gold Jewelry Products
Company Expects to Process at Least 104 Kilograms (approximately 3,668 Ounces) a Month
Kingold Jewelry, Inc. (NASDAQ: KGJI), one of China's leading manufacturers and designers of high quality 24-karat gold jewelry, ornaments and investment-oriented products, today announced that it has entered into a gold-processing agreement with Shenzhen TongXin Jewelry Ltd. ("Shenzhen TongXin"), a large Shenzhen-based wholesaler of jewelry products. Shenzhen TongXin is a leading integrated company in jewelry and precious metal production, processing, wholesaling and refining in Mainland China since 1965. Shenzhen Tongxin is one of the "Famous TradeMarks of China", and its products have been distributed to more than 20 provinces, municipalities and autonomous regions, and have been exported to the United States, South Korea, Russia, France, Germany, Great Britain, Italy and other countries, with annual sales volume of over 40 tons.
Pursuant to the agreement, Kingold will exclusively process a variety of 24-karat gold jewelry products (rings, necklaces, bracelets) for Shenzhen TongXin beginning June 1, 2012 until May 31, 2013. Kingold expects to process at least 104 kilograms, or approximately 3668 ounces, of jewelry products per month until the expiration date of the agreement. Kingold's revenue from this agreement will be derived from its sales price of goods sold upon delivery to Shenzhen TongXin along with its service fees. While pricing is subject to change, based on a current spot price of gold on the date the agreement was executed of approximately US$1,568 per ounce, this would equate to revenues to Kingold of approximately US$5.8 million per month (excluding additional revenues from processing fees). The actual pricing of jewelry products produced under the agreement will be finalized at the time of sale. Pursuant to the terms of the agreement, Kingold holds the right to increase its processing fee if the then-current price of gold falls.
Mr. Zhi Hong Jia, Chairman and Chief Executive Officer of Kingold Jewelry stated, "This agreement is the culmination of a long-process in our discussions with Shenzhen TongXin. The company approached Kingold over two years ago, and began a thorough screening process in evaluating Kingold's processing capabilities, customer service, and quality of product. We are very confident that our quality and reputation within the industry helped greatly in securing this agreement. We are looking forward to working with Shenzhen TongXin, and as always are working towards broadening our base of major distributors and wholesalers."
ROSTOCK VENTURES CORPORATION (OTCBB: ROSV)
"Up 34.29% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/ROSV.php
Rostock Ventures Corp., a natural resource exploration and production company, engages in the exploration, acquisition, and development of mineral properties in the United States. The company holds 59 mineral claims in the Tintina Gold Belt in Yukon, Canada. It also has the rights to an exploration license for approximately 300 hectares located in Hants County, Canada. The company was founded in 2006 and is based in San Diego, California.
ROSV News:
No recent news for Rostock Ventures Corp. (OTCBB: ROSV).
ALEXZA PHARMACEUTICALS INCORPORATED (NASDAQ: ALXA)
"Up 9.84% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/ALXA.php
Alexza Pharmaceuticals, Inc., a development stage company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system that vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company’s clinical-stage product candidates comprise AZ-004 (staccato loxapine), which is licensed to Biovail Laboratories International SRL for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-007 (staccato zaleplon), which completed phase I status for the treatment of insomnia; and AZ-001 (staccato prochlorperazine) and AZ-104 (staccato loxapine, low-dose), phase II product candidates for the treatment of migraine headache. It also develops AZ-002 (Staccato alprazolam), which completed a phase 1 clinical trial in healthy subjects and a phase 2a proof-of-concept clinical trial in panic disorder patients for the treatment of panic attacks; and AZ-003 (Staccato fentanyl) that completed phase 1 clinical trial for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California.
ALXA News:
June 22 - Alexza Announces Resubmission of ADASUVE™ NDA and Provides Regulatory Updates on US and EU Submissions
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012. ADASUVE is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. In the coming weeks, Alexza expects to hear from the FDA regarding the completeness of the resubmitted NDA, the classification of the resubmission (Class 1 or Class 2) and what the new Prescription Drug User Fee Act (PDUFA) goal date will be. Class 1 and Class 2 resubmissions have targeted review periods of 2 months and 6 months, respectively.
ADASUVE NDA Regulatory Update
In May 2012, Alexza received a CRL from the FDA. In the CRL, the FDA noted, "During a recent inspection of the Mountain View, CA manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved." Alexza has stated that it believed the deficiencies were medical device specific and readily addressable. Since the receipt of the CRL, Alexza has received further clarification of the specific deficiencies from the FDA and has made submissions directly to Center for Devices and Radiological Health (CDRH) Office of Compliance and the San Francisco District Office, intended to fully address the deficiencies.
The May 2012 CRL also contained comments on Alexza's draft product labeling. Alexza believes that there is substantial agreement between Alexza and the FDA on product labeling. In the ADASUVE NDA resubmission, Alexza has submitted updated draft labeling which is intended to be responsive to the comments provided by FDA in the May 2012 CRL.
There were no new clinical or safety issues identified and there were no other deficiencies outlined in the CRL. With respect to the ADASUVE Risk Evaluation and Mitigation Strategy (REMS), the CRL stated that discussions can continue on the proposed REMS after the response to the CRL has been submitted. Alexza believes that there is substantial agreement between Alexza and the FDA on the REMS.
ADASUVE MAA Regulatory Update
In March 2012, Alexza received the Committee for Medicinal Products for Human Use Consolidated List of Questions (Day 120 List of Questions) regarding Alexza's ADASUVE Marketing Authorization Application (MAA). The Day 120 List of Questions included major objections pertaining to the extrapolation of Phase 3 clinical efficacy data, aspects of the risk management plan, and the need to obtain an EU Good Manufacturing Practices certificate for Alexza's Mountain View, CA manufacturing facility and commercial manufacturing process.
In May 2012, Alexza and its corporate partner, Grupo Ferrer, met with the Rapporteur, Co-Rapporteur and European Medicines Agency (EMA) to further understand specifics of the major objections raised in the Day 120 List of Questions. Alexza believes it remains on schedule for the targeted early third quarter of 2012 submission of its responses (Day 121 Submission) to the EMA. Also in May, Alexza hosted an EU Pre-Approval Inspection (PAI) by the EMA. The inspection resulted in no findings the EMA would classify as Critical or Major findings.
|
